

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application.

68. (*Currently amended*) A system comprising a solid surface, wherein the surface is attached to:

1) a connecting entity comprising a biotinylated first ligand entity coated onto the surface, and a second ligand comprising avidin, streptavidin or streptactin bound to the first ligand entity via the biotin;

2) a biotinylated chimeric MHC class I monomer comprising a human MHC class I domain and a murine MHC class I domain, wherein said chimeric monomer is bound via the biotin to the avidin, streptavidin or streptactin, and wherein said monomer maintains the ability to assemble into a ternary complex with an MHC binding peptide and beta-2 microglobulin.

69. (*Previously presented*) The system of claim 68, wherein the solid surface is a bead or a microtiter plate.

70. (*Cancelled*) ~~The system of claim 68, wherein said solid surface is coated with a first binding ligand, which is connected to said monomer.~~

71. (*Cancelled*) ~~The system of claim 70, wherein said first binding ligand binds to a second binding ligand, which is attached to said monomer.~~

72. (*Currently amended*) The system of claim ~~70~~ 68, wherein said first ~~binding~~ ligand entity is an avidin or streptavidin bovine serum albumin.

73. (*Cancelled*) ~~The system of claim 72, wherein said second binding ligand is biotin.~~

74. (*Currently amended*) The system of claim ~~73~~ 68, wherein said second ~~binding~~ ligand is attached to a C-terminal end of the monomer.

75. (*Previously presented*) The system of claim 68, wherein said human MHC class I domain is a HLA class I domain.

76. (*Previously presented*) The system of claim 75, wherein the HLA class I domain is from HLA-A.

77. (*Previously presented*) The system of claim 75, wherein the HLA class I domain is from HLA-B or HLA-C.

78. (*Previously presented*) The system of claim 76, wherein said HLA-A is HLA-A*0201, HLA-A * 0301, or HLA-A * 1101.

79. (*Previously presented*) The system of claim 77, wherein said HLA-B is HLA-B * 0702 or HLA-B * 0801.

80. (*Previously presented*) The system of claim 68, wherein said monomer is bound to beta-2 microglobulin.

81. (*Currently amended*) The system of claim 80, wherein said monomer ~~incorporates~~ is bound to a MHC-binding peptide ~~in a solution~~.

82. (*Currently amended*) The system of claim ~~81~~ 68, ~~wherein said monomer is recognized by~~ further comprising a monoclonal antibody that ~~distinguishes between a monomer bound~~ specifically binds to a an epitope present in the chimeric MHC class I monomer bound to a MHC-binding peptide ~~and a monomer that lacks a MHC-binding peptide~~.

83. (*Previously presented*) The system of claim 68, which is in a dried form.

84. (*Previously presented*) The system of claim 68, which is in a buffer solution.

85. (*Previously presented*) A kit comprising the system of claim 68.

86. (*New*) The system of claim 68, wherein for a first period of time a first peptide is bound to said chimeric MHC class I monomer and for a second period of time a second MHC binding peptide is bound to said chimeric MHC class I monomer, wherein at all periods of time the solid surface is attached to said chimeric MHC class I monomer.